Clinical Overview
Loxapine is available in both oral (Loxitane) and inhaled (Adasuve) formulations. The inhaled form is specifically indicated for acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults, providing rapid onset of action for emergency situations.
Primary Clinical Applications
Oral loxapine is used for long-term treatment of schizophrenia, while inhaled loxapine (Adasuve) provides rapid control of acute agitation in hospital settings. The inhaled formulation offers unique advantages for managing psychiatric emergencies.
Mechanism and Onset
Loxapine blocks dopamine and serotonin receptors, with the inhaled formulation achieving therapeutic levels within 10 minutes. This rapid onset makes it valuable for acute agitation management when oral medications are not feasible.
Safety Considerations
The inhaled formulation requires specialized administration in healthcare facilities due to risk of bronchospasm. Patients must be monitored for respiratory adverse effects, and the medication is only available through a restricted program.
Prescribing Information
Dosing & Administration
Adasuve (Inhaled) – Acute Agitation:
- Dose: 10 mg inhaled (one inhalation)
- Maximum: One dose per 24 hours
- Setting: Healthcare facility only with respiratory monitoring
Loxitane (Oral) – Schizophrenia:
- Initial: 10 mg twice daily
- Range: 60-100 mg daily in divided doses
- Maximum: 250 mg daily
Indications
- Adasuve: Acute treatment of agitation in schizophrenia or bipolar I disorder
- Loxitane: Treatment of schizophrenia
Contraindications
- Adasuve: Current diagnosis of asthma, COPD, or other lung disease
- Both: Hypersensitivity to loxapine, severe CNS depression, comatose states
Warnings & Precautions
- Boxed Warning (Adasuve): Risk of bronchospasm; only available through REMS program
- Boxed Warning: Increased mortality in elderly with dementia-related psychosis
- Neuroleptic malignant syndrome risk
- Tardive dyskinesia with chronic use
- Cardiovascular effects: hypotension, tachycardia
- Seizure threshold lowering
Drug Interactions
- CNS depressants: Enhanced sedation and respiratory depression
- Anticholinergic agents: Additive anticholinergic effects
- Antihypertensives: Enhanced hypotensive effects
- Epinephrine: May cause paradoxical hypotension
Adverse Reactions
Adasuve Common:
- Dysgeusia (metallic taste), sedation, throat irritation
Oral Loxapine Common:
- Drowsiness, extrapyramidal symptoms, dry mouth, blurred vision
Serious:
- Bronchospasm (inhaled), neuroleptic malignant syndrome, tardive dyskinesia
Special Populations
- Respiratory Disease: Adasuve contraindicated in any active lung disease
- Elderly: Increased mortality risk, start with lower doses
- Pregnancy: Category C – use only if benefits outweigh risks
- REMS Program: Adasuve requires special certification and monitoring
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
